380 related articles for article (PubMed ID: 20848767)
1. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
Tsuji K; Tsutani K
J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
[TBL] [Abstract][Full Text] [Related]
2. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
Tsuji K; Tsutani K
Eur J Pharm Biopharm; 2008 Mar; 68(3):496-502. PubMed ID: 17884403
[TBL] [Abstract][Full Text] [Related]
3. The notorious "drug lag" for oncology drugs in Japan.
Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies: A 15-year analysis (2004-2018).
Konwar M; Maurya MR; Nishandar TB; Thatte UM; Gogtay NJ
Perspect Clin Res; 2021; 12(3):159-164. PubMed ID: 34386381
[TBL] [Abstract][Full Text] [Related]
5. Drug lag for cardiovascular drug approvals in India compared with the US and EU approvals.
Kataria BC; Mehta DS; Chhaiya SB
Indian Heart J; 2013; 65(1):24-9. PubMed ID: 23438609
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Pediatric Drug Approval Lag in Japan.
Ueyama E; Kaneko M; Narukawa M
Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
[TBL] [Abstract][Full Text] [Related]
7. [Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2006; (124):80-2. PubMed ID: 17405529
[TBL] [Abstract][Full Text] [Related]
8. Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis.
Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
Clin Pharmacol Ther; 2021 May; 109(5):1265-1273. PubMed ID: 33048367
[TBL] [Abstract][Full Text] [Related]
9. Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan.
Hino Y; Okada M; Hallgreen CE; De Bruin ML; Doty RE; Matsumaru N; Tsukamoto K
Biol Pharm Bull; 2023 May; 46(5):700-706. PubMed ID: 36878610
[TBL] [Abstract][Full Text] [Related]
10. Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017.
Lee SW; Park SH; Song I; Noh Y; Park H; Ha D; Shin JY
Ther Innov Regul Sci; 2020 Mar; 54(2):418-423. PubMed ID: 32072585
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
Nagai S; Ozawa K
Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
[TBL] [Abstract][Full Text] [Related]
12. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
Nakayama H; Matsumaru N; Tsukamoto K
Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
[TBL] [Abstract][Full Text] [Related]
13. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
Kawabata-Shoda E; Masuda S; Kimura H
J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
[TBL] [Abstract][Full Text] [Related]
14. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
15. Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia.
Noguchi A; Hanaoka H; Uyama Y
Ther Innov Regul Sci; 2022 May; 56(3):523-529. PubMed ID: 35181842
[TBL] [Abstract][Full Text] [Related]
16. Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison.
Reichert JM; Healy EM
Eur J Pharm Biopharm; 2001 Jan; 51(1):1-7. PubMed ID: 11154897
[TBL] [Abstract][Full Text] [Related]
17. Delays in new drug applications in Japan and industrial R&D strategies.
Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
[TBL] [Abstract][Full Text] [Related]
18. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
19. Comparative Assessment of Drug Lag for Approved Oncology Targeted Therapies Between Saudi Arabia, the United States, and the European Union.
Alnuhait M; Alshammari A; Alharbi M; AlOtaibi L; Alharbi R; Khobrani A; Alkhudair N; Alshamrani M; Alrajhi AM
Ther Innov Regul Sci; 2024 Jul; 58(4):678-686. PubMed ID: 38536660
[TBL] [Abstract][Full Text] [Related]
20. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustà A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
